Short answer
West Pharmaceutical Services (WST) filed an 8-K current report with the SEC on March 9, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure). CEO Eric M. Green retiring as President, CEO, and Board Chair once successor hired: transition expected H2 2026.
West Pharmaceutical Services 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- CEO Eric M. Green retiring as President, CEO, and Board Chair once successor hired: transition expected H2 2026
- Board engaging executive search firm; leadership continuity risk elevated during search period
- Green holds all three top roles simultaneously, making succession planning critical to investor confidence
Item 7.01 · Regulation FD Disclosure
- CEO Eric Green announced intent to retire from West Pharmaceutical Services and its Board of Directors
- Company reaffirmed full-year 2026 financial guidance originally issued in Feb 12, 2026 earnings release
- Guidance reaffirmation signals no material business disruption expected from CEO transition
- CEO succession risk is key investor focus: no successor named in this filing
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other West Pharmaceutical Services 8-K filings
Get the next WST 8-K as it lands
Follow WST for push alerts, or ask the research agent what this filing means.